Olutasidenib
Olutasidenib 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Acute Myeloid Leukemia、Chronic Myelomonocytic Leukemia、Myelodysplastic Syndrome。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。
12 项
全球在招研究
1 项
已进入 III/IV 期
9 个
开展国家和地区
暂未检索到
中国境内设点
药品与企业信息
研发企业
- University of California, Davis
- City of Hope Medical Center
- National Cancer Institute (NCI)
- M.D. Anderson Cancer Center
- Timothy Pardee
- Rigel Pharmaceuticals
- Justin Watts, MD
- Kissei Pharmaceutical Co., Ltd.
汇总自相关试验登记的主要申办方；研究机构申办时会显示相应机构名称。
生产企业
公开药品批准资料或正式说明书暂未提供明确的生产企业信息。
研发企业与生产企业可能不是同一家。研究阶段药品可能尚未公布生产企业；生产企业仅取自美国上市原研药说明书所列企业（不含仿制药），不作推测；仅在其他国家上市的药品暂无法显示。
主要开展国家和地区
美国、加拿大、Puerto Rico、日本、澳大利亚、德国、荷兰、新西兰、英国
正在招募患者的 Olutasidenib 研究
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
II 期招募中美国加拿大Puerto RicoNCT05564390A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia.
II 期招募中美国NCT06566742Olutasidenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received Venetoclax
II 期招募中美国NCT07471841Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies
IV 期招募中美国NCT07486713A Phase II Open-label Study of Olutasidenib Post-transplant Maintenance Therapy for Patients With IDH1-mutated Myeloid Malignancies
II 期招募中美国NCT06668584Olutasidenib With Azacitidine Followed by Olutasidenib Maintenance for the Treatment of IDH1-mutated Acute Myeloid Leukemia in Patients With Prior Treatment With Venetoclax Plus a Hypomethylating Agent
II 期招募中美国NCT07304011Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway Mutations
II 期招募中美国NCT07032727Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for Intensive Induction Chemotherapy
II 期招募中美国NCT06782542Phase 1b/2 Study of Decitabine and Venetoclax in Combination With the Targeted Mutant IDH1 Inhibitor Olutasidenib
I 期 / II 期招募中美国NCT06445959A Clinical Trial of Olutasidenib in Patients With Acute Myeloid Leukemia
II 期招募中日本NCT07604064Olutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell Transplant
I 期招募中美国NCT06543381Study of Olutasidenib and Temozolomide in HGG
II 期招募中美国澳大利亚加拿大德国NCT06161974
中国患者怎么争取用上这款药
目前境内暂未检索到设点，下面几条途径是更现实的选择，每条都有详细的中文做法。
查看完整申请指南同类方向的其他在研新药
本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。